Duaa Jabari, MD
Neurology · Los Angeles, CANPI 1124374442
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,975 of the $9,544 with a category attached, or 73.1%. Sarepta Therapeutics, Inc. accounts for 86.1% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $8,222 and has fallen 98.9% since, to $91 in 2025.
Across 28 payments — averaging $340.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$8K
- Janssen Research & Development, LLC$1K
- Life Molecular Imaging Ltd$91
- Hospira, Inc.$77
- Apria Healthcare LLC$16
Across 25 payments — averaging $2275.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tanabe Pharma America, Inc.$23K
- PTC Therapeutics, Inc.$21K
- Leadiant Biosciences, Inc.$13K
What the payments were for
- Consulting fees$6,97573%
- Travel & lodging$1,92220%
- Food & beverage$6477%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 7 | $8,222 |
| Janssen Research & Development, LLC | 11 | $1,139 |
| Life Molecular Imaging Ltd | 4 | $91 |
| Hospira, Inc. | 5 | $77 |
| Apria Healthcare LLC | 1 | $16 |
How this compares
$9,544 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 65 | $448,952 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 27 | $174,693 |
| Gabapentin | 30 | $328 |
| Duloxetine Hcl | 16 | $230 |
| Prednisone | 12 | $184 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.